This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • FDA approves SenSight directional lead system used...
News

FDA approves SenSight directional lead system used for deep brain stimulation therapy- Medtronic

Read time: 1 mins
Published:14th Jun 2021
Medtronic plc has announced the FDA approval and first U.S. implants of the SenSight Directional Lead System used for Deep Brain Stimulation (DBS) therapy. SenSight is the first-of-its-kind DBS directional lead that combines the benefits of directionality with the power of sensing, allowing physicians to deliver precise, patient-specific DBS therapy for the treatment of some symptoms associated with movement disorders like Parkinson's disease, dystonia and essential tremor, and medically refractory epilepsy.

The product also recently received CE Mark and is fully launched in Western Europe. "Until now, sensing capability and directional leads have not been available in the same DBS system, so we have had to choose one technology or the other, based on the predicted needs of each patient," said Kelly D. Foote, M.D., professor of neurosurgery at University of Florida. "Now, by coupling this new directional lead with a pulse generator capable of brain sensing, we are excited to be able to offer our patients the synergistic benefits of both technologies. Furthermore, the ability to continuously record brain activity while affected patients go about their daily lives is a powerful research tool that is rapidly improving our understanding of these brain circuitry disorders that diminish the lives of so many people.".

Condition: Deep Vein Thrombosis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights